Statin use and histopathological change in patients with non-alcoholic fatty liver disease: a systematic review and meta-analysis

[1] Chalasani N, Younossi Z, Lavine JE, Charlton M, Cusi K, Rinella M, et al. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology. 2018; 67:328–57.ChalasaniNYounossiZLavineJECharltonMCusiKRinellaMet alThe diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver DiseasesHepatology201867328–5710.1002/hep.29367Search in Google Scholar

[2] Ballestri S, Zona S, Targher G, Romagnoli D, Baldelli E, Nascimbeni F, et al. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis. J Gastroenterol Hepatol. 2016; 31:936–44.BallestriSZonaSTargherGRomagnoliDBaldelliENascimbeniFet alNonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndromeEvidence from a systematic review and meta-analysis. J Gastroenterol Hepatol201631936–4410.1111/jgh.13264Search in Google Scholar

[3] Targher G, Byrne CD, Lonardo A, Zoppini G, Barbui C. Non-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysis. J Hepatol. 2016; 65:589–600.TargherGByrneCDLonardoAZoppiniGBarbuiCNon-alcoholic fatty liver disease and risk of incident cardiovascular disease: a meta-analysisJ Hepatol201665589–60010.1016/j.jhep.2016.05.013Search in Google Scholar

[4] Lonardo A, Bellentani S, Argo CK, Ballestri S, Byrne CD, Caldwell SH, et al. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups. Dig Liver Dis. 2015; 47:997–1006.LonardoABellentaniSArgoCKBallestriSByrneCDCaldwellSHet alEpidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groupsDig Liver Dis201547997–100610.1016/j.dld.2015.08.004Search in Google Scholar

[5] Eslami L, Merat S, Malekzadeh R, Nasseri-Moghaddam S, Aramin H. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Cochrane Database Syst Rev. 2013:CD008623. doi: 10.1002/14651858.CD008623.pub2.EslamiLMeratSMalekzadehRNasseri-MoghaddamSAraminHStatins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitisCochrane Database Syst Rev2013CD008623. doi10.1002/14651858.CD008623.pub2.Open DOISearch in Google Scholar

[6] Brunt EM, Janney CG, Di Bisceglie AM, Neuschwander-Tetri BA, Bacon BR. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol. 1999; 94:2467–74.BruntEMJanneyCGDiBisceglie AMNeuschwander-TetriBABaconBRNonalcoholic steatohepatitis: a proposal for grading and staging the histological lesionsAm J Gastroenterol1999942467–7410.1111/j.1572-0241.1999.01377.xSearch in Google Scholar

[7] Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41:1313–21.KleinerDEBruntEMVanNatta MBehlingCContosMJCummingsOWet alDesign and validation of a histological scoring system for nonalcoholic fatty liver diseaseHepatology2005411313–2110.1002/hep.20701Search in Google Scholar

[8] Sterne JA, Hernán MA, Reeves BC, Savović J, Berkman ND, Viswanathan M, et al. ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions. BMJ. 2016; 355:i4919. doi: 10.1136/bmj.i4919SterneJAHernánMAReevesBCSavovićJBerkmanNDViswanathanMet alROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventionsBMJ2016355i491910.1136/bmj.i4919Open DOISearch in Google Scholar

[9] Schuünemann H BJ, Guyatt G, Oxman A, editors. GRADE handbook for grading quality of evidence and strength of recommendations [Internet]. The GRADE Working Group; 2013 [updated October 2013; cited 2017 June 02]. Available from: http://gdt.guidelinedevelopment.org/app/handbook/handbook.htmlSchuünemannH BJGuyattGOxmanAeditorsGRADE handbook for grading quality of evidence and strength of recommendations [Internet]The GRADE Working Group;2013[updated October 2013; cited 2017 June 02]. Available fromhttp://gdt.guidelinedevelopment.org/app/handbook/handbook.htmlSearch in Google Scholar

[10] DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7:177–88.DerSimonianRLairdNMeta-analysis in clinical trialsControl Clin Trials19867177–8810.1016/0197-2456(86)90046-2Search in Google Scholar

[11] Huedo-Medina TB, Sánchez-Meca J, Marín-Martínez F, Botella J. Assessing heterogeneity in meta-analysis: Q statistic or I2 index? Psychol Methods. 2006; 11:193–206.Huedo-MedinaTBSánchez-MecaJMarín-MartínezFBotellaJAssessing heterogeneity in meta-analysis: Q statistic or I2 index?Psychol Methods200611193–20610.1037/1082-989X.11.2.19316784338Search in Google Scholar

[12] Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315:629–34.EggerMDaveySmith GSchneiderMMinderCBias in meta-analysis detected by a simple, graphical testBMJ1997315629–3410.1136/bmj.315.7109.629Search in Google Scholar

[13] Ekstedt M, Franzén LE, Mathiesen UL, Holmqvist M, Bodemar G, Kechagias S. Statins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up study. J Hepatol. 2007; 47:135–41.EkstedtMFranzénLEMathiesenULHolmqvistMBodemarGKechagiasSStatins in non-alcoholic fatty liver disease and chronically elevated liver enzymes: A histopathological follow-up studyJ Hepatol200747135–4110.1016/j.jhep.2007.02.013Search in Google Scholar

[14] Hyogo H, Ikegami T, Tokushige K, Hashimoto E, Inui K, Matsuzaki Y, et al. Efficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot study. Hepatol Res. 2011; 41:1057–65.HyogoHIkegamiTTokushigeKHashimotoEInuiKMatsuzakiYet alEfficacy of pitavastatin for the treatment of non-alcoholic steatohepatitis with dyslipidemia: An open-label, pilot studyHepatol Res2011411057–6510.1111/j.1872-034X.2011.00849.xSearch in Google Scholar

[15] Nakahara T, Hyogo H, Kimura Y, Ishitobi T, Arihiro K, Aikata H, et al. Efficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia: an open-label, pilot study. Hepatol Res. 2012; 42:1065–72.NakaharaTHyogoHKimuraYIshitobiTArihiroKAikataHet alEfficacy of rosuvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia: an open-label, pilot studyHepatol Res2012421065–7210.1111/j.1872-034X.2012.01034.xSearch in Google Scholar

[16] Hyogo H, Yamagishi S, Maeda S, Kimura Y, Ishitobi T, Chayama K. Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property. Dig Liver Dis. 2012; 44:492–6.HyogoHYamagishiSMaedaSKimuraYIshitobiTChayamaKAtorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering propertyDig Liver Dis201244492–610.1016/j.dld.2011.12.013Search in Google Scholar

[17] Kargiotis K, Athyros VG, Giouleme O, Katsiki N, Katsiki E, Anagnostis P, et al. Resolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndrome. World J Gastroenterol. 2015; 21:7860–8.KargiotisKAthyrosVGGioulemeOKatsikiNKatsikiEAnagnostisPet alResolution of non-alcoholic steatohepatitis by rosuvastatin monotherapy in patients with metabolic syndromeWorld J Gastroenterol2015217860–810.3748/wjg.v21.i25.7860Search in Google Scholar

[18] Nelson A, Torres DM, Morgan AE, Fincke C, Harrison SA. A pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trial. J Clin Gastroenterol. 2009; 43:990–4.NelsonATorresDMMorganAEFinckeCHarrisonSAA pilot study using simvastatin in the treatment of nonalcoholic steatohepatitis: a randomized placebo-controlled trialJ Clin Gastroenterol200943990–410.1097/MCG.0b013e31819c392eSearch in Google Scholar

[19] Athyros VG, Tziomalos K, Gossios TD, Griva T, Anagnostis P, Kargiotis K, et al.; GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysis. Lancet. 2010; 376:1916–22.AthyrosVGTziomalosKGossiosTDGrivaTAnagnostisPKargiotisKet al.;GREACE Study Collaborative Group. Safety and efficacy of long-term statin treatment for cardiovascular events in patients with coronary heart disease and abnormal liver tests in the Greek Atorvastatin and Coronary Heart Disease Evaluation (GREACE) Study: a post-hoc analysisLancet20103761916–2210.1016/S0140-6736(10)61272-XSearch in Google Scholar

[20] Simon TG, King LY, Zheng H, Chung RT. Statin use is associated with a reduced risk of fibrosis progression in chronic hepatitis C. J Hepatol. 2015; 62:18–23.SimonTGKingLYZhengHChungRTStatin use is associated with a reduced risk of fibrosis progression in chronic hepatitis CJ Hepatol20156218–2310.1016/j.jhep.2014.08.013427264225135867Search in Google Scholar

[21] Henderson LM, Patel S, Giordano TP, Green L, El-Serag HB. Statin therapy and serum transaminases among a cohort of HCV-infected veterans. Dig Dis Sci. 2010; 55:190–5.HendersonLMPatelSGiordanoTPGreenLEl-SeragHBStatin therapy and serum transaminases among a cohort of HCV-infected veteransDig Dis Sci201055190–510.1007/s10620-009-0959-1369885319731022Search in Google Scholar

[22] Kumar S, Grace ND, Qamar AA. Statin use in patients with cirrhosis: a retrospective cohort study. Dig Dis Sci. 2014; 59: 1958–65.KumarSGraceNDQamarAAStatin use in patients with cirrhosis: a retrospective cohort studyDig Dis Sci2014591958–6510.1007/s10620-014-3179-224838495Search in Google Scholar

[23] Butt AA, Yan P, Bonilla H, Abou-Samra AB, Shaikh OS, Simon TG, et al. Effect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVES. Hepatology. 2015; 62:365–74.ButtAAYanPBonillaHAbou-SamraABShaikhOSSimonTGet alEffect of addition of statins to antiviral therapy in hepatitis C virus-infected persons: results from ERCHIVESHepatology201562365–7410.1002/hep.2783525847403Search in Google Scholar

[24] Yang YH, Chen WC, Tsan YT, Chen MJ, Shih WT, Tsai YH, et al. Statin use and the risk of cirrhosis development in patients with hepatitis C virus infection. J Hepatol. 2015; 63:1111–7.YangYHChenWCTsanYTChenMJShihWTTsaiYHet alStatin use and the risk of cirrhosis development in patients with hepatitis C virus infectionJ Hepatol2015631111–710.1016/j.jhep.2015.07.00626196278Search in Google Scholar

[25] Ábel T, Fehér J, Dinya E, Eldin MG, Kovács A. Safety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease. Med Sci Monit. 2009; 15:MS6–11.ÁbelTFehérJDinyaEEldinMGKovácsASafety and efficacy of combined ezetimibe/simvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver diseaseMed Sci Monit2009156–11Search in Google Scholar

[26] Lewis JH, Mortensen ME, Zweig S, Fusco MJ, Medoff JR, Belder R, et al.; Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trial. Hepatology. 2007; 46:1453–63.LewisJHMortensenMEZweigSFuscoMJMedoffJRBelderRet al.;Pravastatin in Chronic Liver Disease Study Investigators. Efficacy and safety of high-dose pravastatin in hypercholesterolemic patients with well-compensated chronic liver disease: Results of a prospective, randomized, double-blind, placebo-controlled, multicenter trialHepatology2007461453–6310.1002/hep.2184817668878Search in Google Scholar

[27] Gomez-Domínguez E, Gisbert JP, Moreno-Monteagudo JA, García-Buey L, Moreno-Otero R. A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patients. Aliment Pharmacol Ther. 2006; 23:1643–7.Gomez-DomínguezEGisbertJPMoreno-MonteagudoJAGarcía-BueyLMoreno-OteroR.A pilot study of atorvastatin treatment in dyslipemid, non-alcoholic fatty liver patientsAliment Pharmacol Ther2006231643–710.1111/j.1365-2036.2006.02926.x16696815Search in Google Scholar

[28] Kiyici M, Gulten M, Gurel S, Nak SG, Dolar E, Savci G, et al. Ursodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitis. Can J Gastroenterol. 2003; 17:713–8.KiyiciMGultenMGurelSNakSGDolarESavciGet alUrsodeoxycholic acid and atorvastatin in the treatment of nonalcoholic steatohepatitisCan J Gastroenterol200317713–810.1155/2003/85786914679419Search in Google Scholar

[29] Athyros VG, Mikhailidis DP, Didangelos TP, Giouleme OI, Liberopoulos EN, Karagiannis A, et al. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr Med Res Opin. 2006; 22:873–83.AthyrosVGMikhailidisDPDidangelosTPGioulemeOILiberopoulosENKaragiannisAet alEffect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised studyCurr Med Res Opin200622873–8310.1185/030079906X10469616709309Search in Google Scholar

[30] Samy W, Hassanian MA. Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin. Arab J Gastroenterol. 2011; 12:80–5.SamyWHassanianMAParaoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatinArab J Gastroenterol20111280–510.1016/j.ajg.2011.04.00821684478Search in Google Scholar

[31] Antonopoulos S, Mikros S, Mylonopoulou M, Kokkoris S, Giannoulis G. Rosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patients. Atherosclerosis. 2006; 184:233–4.AntonopoulosSMikrosSMylonopoulouMKokkorisSGiannoulisGRosuvastatin as a novel treatment of non-alcoholic fatty liver disease in hyperlipidemic patientsAtherosclerosis2006184233–410.1016/j.atherosclerosis.2005.08.02116168995Search in Google Scholar

[32] Riley P, Sudarshi D, Johal M, Benedict A, Panteli J, Crook M, O’Donohue J. Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective study. Int J Clin Pract. 2008; 62:374–81.RileyPSudarshiDJohalMBenedictAPanteliJCrookMO’DonohueJ.Weight loss, dietary advice and statin therapy in non-alcoholic fatty liver disease: a retrospective studyInt J Clin Pract200862374–8110.1111/j.1742-1241.2007.01666.x18201181Search in Google Scholar

[33] Foster T, Budoff MJ, Saab S, Ahmadi N, Gordon C, Guerci AD. Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial. Am J Gastroenterol. 2011; 106:71–7.FosterTBudoffMJSaabSAhmadiNGordonCGuerciADAtorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trialAm J Gastroenterol201110671–710.1038/ajg.2010.29920842109Search in Google Scholar

[34] Oni ET, Sinha P, Karim A, Martin SS, Blaha MJ, Agatston AS, et al. Statin use is not associated with presence of and severity of nonalcoholic fatty liver disease. Arch Med Res. 2014; 45:52–7.OniETSinhaPKarimAMartinSSBlahaMJAgatstonASet alStatin use is not associated with presence of and severity of nonalcoholic fatty liver diseaseArch Med Res20144552–710.1016/j.arcmed.2013.12.00324333254Search in Google Scholar

[35] Avins AL, Manos MM, Ackerson L, Zhao W, Murphy R, Levin TR, et al. Hepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort study. Drug safety. 2008; 31:325–34.AvinsALManosMMAckersonLZhaoWMurphyRLevinTRet alHepatic effects of lovastatin exposure in patients with liver disease: a retrospective cohort studyDrug safety200831325–3410.2165/00002018-200831040-0000618366243Search in Google Scholar

[36] Dongiovanni P, Petta S, Mannisto V, Mancina RM, Pipitone R, Karja V, et al. Statin use and non-alcoholic steatohepatitis in at risk individuals. J Hepatol. 2015; 63:705–12.DongiovanniPPettaSMannistoVMancinaRMPipitoneRKarjaVet alStatin use and non-alcoholic steatohepatitis in at risk individualsJ Hepatol201563705–1210.1016/j.jhep.2015.05.00625980762Search in Google Scholar

[37] Mihaila RG, Nedelcu L, Fratila O, Rezi EC, Domnariu C, Deac M. Effects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitis. Hepatogastroenterology. 2009; 56:1117–21.MihailaRGNedelcuLFratilaOReziECDomnariuCDeacMEffects of lovastatin and pentoxyphyllin in nonalcoholic steatohepatitisHepatogastroenterology2009561117–21Search in Google Scholar

[38] Rallidis LS, Drakoulis CK, Parasi AS. Pravastatin in patients with nonalcoholic steatohepatitis: results of a pilot study. Atherosclerosis. 2004; 174:193–6.RallidisLSDrakoulisCKParasiASPravastatin in patients with nonalcoholic steatohepatitis: results of a pilot studyAtherosclerosis2004174193–610.1016/j.atherosclerosis.2004.01.00815135271Search in Google Scholar

[39] Georgescu EF, Georgescu M. Therapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary study. J Gastrointestin Liver Dis. 2007; 16:39–46.GeorgescuEFGeorgescuMTherapeutic options in non-alcoholic steatohepatitis (NASH). Are all agents alike? Results of a preliminary studyJ Gastrointestin Liver Dis20071639–46Search in Google Scholar

[40] Kimura Y, Hyogo H, Yamagishi S, Takeuchi M, Ishitobi T, Nabeshima Y, et al. Atorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASH. J Gastroenterol. 2010; 45:750–7.KimuraYHyogoHYamagishiSTakeuchiMIshitobiTNabeshimaYet alAtorvastatin decreases serum levels of advanced glycation endproducts (AGEs) in nonalcoholic steatohepatitis (NASH) patients with dyslipidemia: clinical usefulness of AGEs as a biomarker for the attenuation of NASHJ Gastroenterol201045750–710.1007/s00535-010-0203-y20112031Search in Google Scholar

[41] Hyogo H, Tazuma S, Arihiro K, Iwamoto K, Nabeshima Y, Inoue M, et al. Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia. Metabolism. 2008; 57:1711–8.HyogoHTazumaSArihiroKIwamotoKNabeshimaYInoueMet alEfficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemiaMetabolism2008571711–810.1016/j.metabol.2008.07.03019013295Search in Google Scholar

[42] Iwaisako K, Brenner DA, Kisseleva T. What’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosis. J Gastroenterol Hepatol. 2012; 27(Suppl 2):65–8.IwaisakoKBrennerDAKisselevaTWhat’s new in liver fibrosis? The origin of myofibroblasts in liver fibrosisJ Gastroenterol Hepatol201227Suppl 265–810.1111/j.1440-1746.2011.07002.x484126822320919Search in Google Scholar

[43] Kisseleva T, Brenner DA. Mechanisms of fibrogenesis. Exp Biol Med. 2008; 233:109–22.KisselevaTBrennerDAMechanisms of fibrogenesisExp Biol Med2008233109–2210.3181/0707-MR-19018222966Search in Google Scholar

[44] Kuoppala J, Lamminpää A, Pukkala E. Statins and cancer: a systematic review and meta-analysis. Eur J Cancer. 2008; 44:2122–32.KuoppalaJLamminpääAPukkalaEStatins and cancer: a systematic review and meta-analysisEur J Cancer2008442122–3210.1016/j.ejca.2008.06.02518707867Search in Google Scholar

[45] Rao S, Porter DC, Chen X, Herliczek T, Lowe M, Keyomarsi K. Lovastatin-mediated G₁ arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductase. Proc Natl Acad Sci U S A. 1999; 96:7797–802.RaoSPorterDCChenXHerliczekTLoweMKeyomarsiKLovastatin-mediatedG₁ arrest is through inhibition of the proteasome, independent of hydroxymethyl glutaryl-CoA reductaseProc Natl Acad Sci U S A1999967797–80210.1073/pnas.96.14.7797Search in Google Scholar

[46] Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 371:838–51.SchuppanDAfdhalNHLiver cirrhosisLancet2008371838–5110.1016/S0140-6736(08)60383-9Search in Google Scholar

[47] Sun H-Y, Singh N. Antimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipients. Clin Infect Dis. 2009; 48:745–55.SunH-YSinghNAntimicrobial and immunomodulatory attributes of statins: relevance in solid-organ transplant recipientsClin Infect Dis200948745–5510.1086/59703919193110Search in Google Scholar

[48] Wu J, Wong W-W, Khosravi F, Minden MD, Penn LZ. Blocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosis. Cancer Res. 2004; 64:6461–8.WuJWongW-WKhosraviFMindenMDPennLZBlocking the Raf/MEK/ERK pathway sensitizes acute myelogenous leukemia cells to lovastatin-induced apoptosisCancer Res2004646461–810.1158/0008-5472.CAN-04-086615374955Search in Google Scholar

[49] Simon TG, Butt AA. Lipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomes. World J Gastroenterol. 2015; 21:8293–303.SimonTGButtAALipid dysregulation in hepatitis C virus, and impact of statin therapy upon clinical outcomesWorld J Gastroenterol2015218293–30310.3748/wjg.v21.i27.8293450709926217081Search in Google Scholar

[50] Okada Y, Yamaguchi K, Nakajima T, Nishikawa T, Jo M, Mitsumoto Y, et al. Rosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in rats. Liver Int. 2013; 33:301–11.OkadaYYamaguchiKNakajimaTNishikawaTJoMMitsumotoYet alRosuvastatin ameliorates high-fat and high-cholesterol diet-induced nonalcoholic steatohepatitis in ratsLiver Int201333301–1110.1111/liv.1203323295058Search in Google Scholar

[51] Van Rooyen DM, Gan LT, Yeh MM, Haigh WG, Larter CZ, Ioannou G, et al. Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome. J Hepatol. 2013; 59:144–52.VanRooyen DMGanLTYehMMHaighWGLarterCZIoannouGet alPharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndromeJ Hepatol201359144–5210.1016/j.jhep.2013.02.02423500152Search in Google Scholar

[52] Wang W, Zhao C, Zhou J, Zhen Z, Wang Y, Shen C. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One. 2013; 8:e76538. doi: 10.1371/journal.pone.0076538WangWZhaoCZhouJZhenZWangYShenCSimvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosisPLoS One20138e7653810.1371/journal.pone.0076538378873224098525Open DOISearch in Google Scholar

[53] Pramfalk C, Parini P, Gustafsson U, Sahlin S, Eriksson M. Effects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolism. J Intern Med. 2011; 269:333–9.PramfalkCPariniPGustafssonUSahlinSErikssonMEffects of high-dose statin on the human hepatic expression of genes involved in carbohydrate and triglyceride metabolismJ Intern Med2011269333–910.1111/j.1365-2796.2010.02305.x21083855Search in Google Scholar

[54] Trebicka J, Schierwagen R. Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension. Gut. 2015; 64:1349–50.TrebickaJSchierwagenRStatins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertensionGut2015641349–5010.1136/gutjnl-2014-30880025596180Search in Google Scholar

[55] Singh S, Allen AM, Wang Z, Prokop LJ, Murad MH, Loomba R. Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies. Clin Gastroenterol Hepatol. 2015; 13:643–54.SinghSAllenAMWangZProkopLJMuradMHLoombaRFibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studiesClin Gastroenterol Hepatol201513643–5410.1016/j.cgh.2014.04.014420897624768810Search in Google Scholar

[56] Gazzerro P, Proto MC, Gangemi G, Malfitano AM, Ciaglia E, Pisanti S, et al. Pharmacological actions of statins: a critical appraisal in the management of cancer. Pharmacol Rev. 2012; 64:102–46.GazzerroPProtoMCGangemiGMalfitanoAMCiagliaEPisantiSet alPharmacological actions of statins: a critical appraisal in the management of cancerPharmacol Rev201264102–4610.1124/pr.111.00499422106090Search in Google Scholar

[57] Lins RL, Matthys KE, Verpooten GA, Peeters PC, Dratwa M, Stolear J-C, et al. Pharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patients. Nephrol Dial Transplant. 2003; 18:967–76.LinsRLMatthysKEVerpootenGAPeetersPCDratwaMStolearJ-Cet alPharmacokinetics of atorvastatin and its metabolites after single and multiple dosing in hypercholesterolaemic haemodialysis patientsNephrol Dial Transplant200318967–7610.1093/ndt/gfg04812686673Search in Google Scholar

[58] Bologa R, Levine D, Parker T, Gordon B, Lanto A, Cheigh J, et al. Pharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysis. Clin Nephrol. 2009; 72:437–41.BologaRLevineDParkerTGordonBLantoACheighJet alPharmacokinetics of rosuvastatin in patients with end-stage kidney disease undergoing peritoneal dialysisClin Nephrol200972437–4110.5414/CNP7243719954720Search in Google Scholar

[59] Hui CK, Cheung BM, Lau GK. Pharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosis. Br J Clin Pharmacol. 2005; 59:291–7.HuiCKCheungBMLauGKPharmacokinetics of pitavastatin in subjects with Child-Pugh A and B cirrhosisBr J Clin Pharmacol200559291–710.1111/j.1365-2125.2004.02251.x188478115752374Search in Google Scholar

[60] Pastori D, Polimeni L, Baratta F, Pani A, Del Ben M, Angelico F. The efficacy and safety of statins for the treatment of non-alcoholic fatty liver disease. Dig Liver Dis. 2015; 47:4–11.PastoriDPolimeniLBarattaFPaniADelBen MAngelicoFThe efficacy and safety of statins for the treatment of non-alcoholic fatty liver diseaseDig Liver Dis2015474–1110.1016/j.dld.2014.07.17025224698Search in Google Scholar

[61] Postmus I, Trompet S, Deshmukh HA, Barnes MR, Li X, Warren HR, et al. Pharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statins. Nat Commun. 2014; 5:5068. doi: 10.1038/ncomms6068PostmusITrompetSDeshmukhHABarnesMRLiXWarrenHRet alPharmacogenetic meta-analysis of genome-wide association studies of LDL cholesterol response to statinsNat Commun20145506810.1038/ncomms6068422046425350695Open DOISearch in Google Scholar

[62] Rzouq FS, Volk ML, Hatoum HH, Talluri SK, Mummadi RR, Sood GK. Hepatotoxicity fears contribute to underutilization of statin medications by primary care physicians. Am J Med Sci. 2010; 340:89–93.RzouqFSVolkMLHatoumHHTalluriSKMummadiRRSoodGKHepatotoxicity fears contribute to underutilization of statin medications by primary care physiciansAm J Med Sci201034089–9310.1097/MAJ.0b013e3181e15da820588181Search in Google Scholar

[63] Onofrei MD, Butler KL, Fuke DC, Miller HB. Safety of statin therapy in patients with preexisting liver disease. Pharmacotherapy. 2008; 28:522–9.OnofreiMDButlerKLFukeDCMillerHBSafety of statin therapy in patients with preexisting liver diseasePharmacotherapy200828522–910.1592/phco.28.4.52218363535Search in Google Scholar

[64] Imprialos KP, Stavropoulos K, Doumas M, Skalkou A, Zografou I, Athyros VG. The potential role of statins in treating liver disease. Expert Rev Gastroenterol Hepatol. 2018; 12:331–9.ImprialosKPStavropoulosKDoumasMSkalkouAZografouIAthyrosVGThe potential role of statins in treating liver diseaseExpert Rev Gastroenterol Hepatol201812331–910.1080/17474124.2018.143937929431526Search in Google Scholar

[65] Bril F, Portillo Sanchez P, Lomonaco R, Orsak B, Hecht J, Tio F, et al. Liver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post-hoc analysis of a randomized trial. J Clin Endocrinol Metab. 2017; 102:2950–61.BrilFPortilloSanchez PLomonacoROrsakBHechtJTioFet alLiver safety of statins in prediabetes or T2DM and nonalcoholic steatohepatitis: post-hoc analysis of a randomized trialJ Clin Endocrinol Metab20171022950–6110.1210/jc.2017-00867554685028575232Search in Google Scholar

[66] Han KH, Rha SW, Kang H-J, Bae J-W, Choi B-J, Choi S-Y, et al. Evaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage). J Clin Lipidol. 2012; 6:340–51.HanKHRhaSWKangH-JBaeJ-WChoiB-JChoiS-Yet alEvaluation of short-term safety and efficacy of HMG-CoA reductase inhibitors in hypercholesterolemic patients with elevated serum alanine transaminase concentrations: PITCH study (PITavastatin versus atorvastatin to evaluate the effect on patients with hypercholesterolemia and mild to moderate hepatic damage)J Clin Lipidol20126340–5110.1016/j.jacl.2012.01.00922836071Search in Google Scholar

[67] Angulo P, Kleiner DE, Dam-Larsen S, Adams LA, Bjornsson ES, Charatcharoenwitthaya P, et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. 2015; 149:389–97.AnguloPKleinerDEDam-LarsenSAdamsLABjornssonESCharatcharoenwitthayaPet alLiver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver diseaseGastroenterology2015149389–9710.1053/j.gastro.2015.04.043451666425935633Search in Google Scholar

[68] Athyros VG, Tziomalos K, Katsiki N, Doumas M, Karagiannis A, Mikhailidis DP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update. World J Gastroenterol. 2015; 21:6820–34.AthyrosVGTziomalosKKatsikiNDoumasMKaragiannisAMikhailidisDPCardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An updateWorld J Gastroenterol2015216820–3410.3748/wjg.v21.i22.6820446272226078558Search in Google Scholar

[69] Singh S, Khera R, Allen AM, Murad MH, Loomba R. Comparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysis. Hepatology. 2015; 62:1417–32.SinghSKheraRAllenAMMuradMHLoombaRComparative effectiveness of pharmacological interventions for nonalcoholic steatohepatitis: A systematic review and network meta-analysisHepatology2015621417–3210.1002/hep.2799926189925Search in Google Scholar